Molecular basis and outcomes of atypical haemolytic uraemic syndrome in Czech children

被引:6
作者
Stolbova, Sarka [1 ,2 ]
Bezdicka, Martin [1 ,2 ]
Prohaszka, Zoltan [3 ,4 ]
Csuka, Dorottya [3 ,4 ]
Hrachovinova, Ingrid [5 ]
Burkert, Jan [2 ,6 ]
Simankova, Nadezda [1 ,2 ]
Pruhova, SStepanka [1 ,2 ]
Zieg, Jakub [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med 2, Dept Paediat, Prague, Czech Republic
[2] Motol Univ Hosp, Prague, Czech Republic
[3] Hungarian Acad Sci, Dept Med 3, Budapest, Hungary
[4] Hungarian Acad Sci, MTA SE Res Grp Immunol & Haematol, Budapest, Hungary
[5] Inst Hematol & Blood Transfus, Prague, Czech Republic
[6] Charles Univ Prague, Fac Med 2, Dept Cardiovasc Surg, Prague, Czech Republic
关键词
Alternative complement pathway; Anti-complement factor H antibodies; Atypical haemolytic uraemic syndrome; Children; DGKE; Next-generation sequencing; FACTOR-H-AUTOANTIBODIES; COMPLEMENT MUTATIONS; ECULIZUMAB; IMPACT; GENE; CFHR1;
D O I
10.1007/s00431-020-03666-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Atypical haemolytic uraemic syndrome is an ultra-rare, life-threatening disease. Causative variants in genes that encode complement factors can be identified in 40-70% of cases. We performed genetic analysis of 21 Czech children with atypical haemolytic uraemic syndrome. Genetic or acquired predisposition to the disease was identified in the majority of our patients: CFHR1 and CFHR3 deletions in 14/21 (67%; 13 of them were positive for anti-complement factor H antibodies), variants in complement genes or DGKE in 13/21 (62%). Multiple genetic findings were identified in eight patients (38%). The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population was estimated to be 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period. Ten patients were initially treated with plasma exchange and eight with eculizumab or with a combination of eculizumab and plasma exchange. At the last follow-up, 20 patients were alive and one patient had end-stage renal disease. Conclusion: The incidence of atypical haemolytic uraemic syndrome in the Czech paediatric population corresponds to the reported incidence in Europe. We detected the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies in Czech paediatric patients. Treatment by eculizumab led to superior outcomes and prevention of the disease relapses compared with plasma exchange therapy. Our results may help to understand the polygenic nature of atypical haemolytic uraemic syndrome as a disease that results from a combination of various risk factors.What is Known: center dot Atypical haemolytic uraemic syndrome (aHUS) is considered a polygenic and multifactorial disease. Genetic predisposition to aHUS is identified in 40-70% of children. center dot Anti-complement factor H antibodies are usually found in 6-25% of affected children.What is New: center dot Potentially causative genetic or acquired factors were confirmed in the majority of patients. The prevailing finding was the unusually high rate of CFHR1/CFHR3 deletions associated with anti-complement factor H antibodies (62% of patients). center dot The incidence of aHUS in Czech children is 0.092 (CI 0.053-0.131) cases per million inhabitants and 0.92 (CI 0.53-1.32) cases per 100,000 births for the entire reporting period.
引用
收藏
页码:1739 / 1750
页数:12
相关论文
共 50 条
  • [41] Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS)
    Westra, Dineke
    Volokhina, Elena
    van der Heijden, Eefje
    Vos, Annemieke
    Huigen, Marleen
    Jansen, Jitske
    van Kaauwen, Edwin
    van der Velden, Thea
    van de Kar, Nicole
    van den Heuvel, Lambert
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (07) : 2195 - 2202
  • [42] Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases
    Kwon, Theresa
    Belot, Alexandre
    Ranchin, Bruno
    Baudouin, Veronique
    Fremeaux-Bacchi, Veronique
    Dragon-Durey, Marie-Agnes
    Cochat, Pierre
    Loirat, Chantal
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (09) : 2752 - 2754
  • [43] Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis
    Kim, Jon Jin
    Waller, Simon C.
    Reid, Christopher J.
    [J]. CLINICAL KIDNEY JOURNAL, 2012, 5 (01): : 34 - 36
  • [44] Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study
    Portoles, Jose
    Huerta, Ana
    Arjona, Emilia
    Gavela, Eva
    Aguera, Marisa
    Jimenez, Carlos
    Cavero, Teresa
    Marrero, Domingo
    Rodriguez de Cordoba, Santiago
    Diekmann, Fritz
    [J]. CLINICAL KIDNEY JOURNAL, 2021, 14 (04) : 1173 - 1180
  • [45] Eculizumab in atypical haemolytic uraemic syndrome with severe cardiac and neurological involvement
    Hushi Hu
    Arvind Nagra
    Mushfequr R. Haq
    Rodney D. Gilbert
    [J]. Pediatric Nephrology, 2014, 29 : 1103 - 1106
  • [46] Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome
    Mahmood, Usman
    Isbel, Nicole
    Mollee, Peter
    Mallett, Andrew
    Govindarajulu, Sridevi
    Francis, Ross
    [J]. NEPHROLOGY, 2017, 22 : 15 - 17
  • [47] Individualised therapeutic approach to the patient with atypical haemolytic-uraemic syndrome
    Mikacic, Ivana
    Maric, Nikolina
    [J]. CLINICAL MEDICINE, 2024, 24 (06)
  • [48] An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document
    Campistol, Josep M.
    Arias, Manuel
    Ariceta, Gema
    Blasco, Miguel
    Espinosa, Laura
    Espinosa, Mario
    Grinyo, Josep M.
    Macia, Manuel
    Mendizabal, Santiago
    Praga, Manuel
    Roman, Elena
    Torra, Roser
    Valdes, Francisco
    Vilalta, Ramon
    Rodriguez de Cordoba, Santiago
    [J]. NEFROLOGIA, 2015, 35 (05): : 421 - 447
  • [49] Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan
    Ito, Shuichi
    Hataya, Hiroshi
    Ashida, Akira
    Hamada, Riku
    Ishikawa, Tomoaki
    Ishikawa, Yumiko
    Shimono, Akihiko
    Konomoto, Takao
    Miyazawa, Tomoki
    Ogura, Masao
    Tanaka, Kazuki
    Kagami, Shoji
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 (02) : 414 - 424
  • [50] Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy
    Neave, Lucy
    Gale, Daniel P.
    Cheesman, Simon
    Shah, Raakhee
    Scully, Marie
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 113 - 124